Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

F6807

Sigma-Aldrich

Fleroxacin

Sinonimo/i:

RO 23-6240, 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid, 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, AM-833, Megalocin, Megalone

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C17H18F3N3O3
Numero CAS:
79660-72-3
Peso molecolare:
369.34
Numero MDL:
MFCD00864880
Codice UNSPSC:
51102829
ID PubChem:
329799758
NACRES:
NA.85

Saggio

≥98% (HPLC)

Stato

solid

Colore

white to off-white

Solubilità

0.1 M NaOH: 10 mg/mL

Spettro attività antibiotica

Gram-negative bacteria
Gram-positive bacteria
mycobacteria
mycoplasma

Modalità d’azione

DNA synthesis | interferes
enzyme | inhibits

Temperatura di conservazione

−20°C

Stringa SMILE

CN1CCN(CC1)c2c(F)cc3C(=O)C(=CN(CCF)c3c2F)C(O)=O

InChI

1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
XBJBPGROQZJDOJ-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It is used in pharmacokinetic studies and is used to study the treatment of intra-abdominal abscesses and travellers′ diarrhea[1][2][3].

Azioni biochim/fisiol

Fleroxacin is a synthetic trifluorinated quinolone with antimicrobial activity against a variety of pathogens, including mycobacteria, mycoplasmas, chlamydiae, and legionellae. It strongly inhibits the DNA-supercoiling activity of DNA gyrase and DNA topoisomerase 2, which results in cell death[4].

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
MKCL5091
080M1481

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

J C Akaniro et al.
Antimicrobial agents and chemotherapy, 34(10), 1880-1884 (1990-10-01)
We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis. These isolates included rough and mucoid Pseudomonas aeruginosa, Pseudomonas cepacia, Staphylococcus aureus, Haemophilus influenzae, and Escherichia coli. Selected isolates were tested by the broth microdilution
R Steffen et al.
The Journal of antimicrobial chemotherapy, 31(5), 767-776 (1993-05-01)
A double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of fleroxacin for one or two days as treatment for patients with travellers' diarrhoea. A total of 195 patients who were suffering with acute diarrhoea of less
A Pefanis et al.
Antimicrobial agents and chemotherapy, 38(2), 252-255 (1994-02-01)
To assess the potential efficacy of fleroxacin in combination with clindamycin or metronidazole in mixed aerobic and anaerobic infections, we used a rat model of intra-abdominal abscesses in which the inoculum consisted of pooled rat feces mixed with BaSO4. Two
R A Blouin et al.
Antimicrobial agents and chemotherapy, 36(3), 632-638 (1992-03-01)
In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated. Fleroxacin (400 mg) was administered orally and
Yanqing Wang et al.
Talanta, 77(5), 1667-1674 (2009-01-23)
This paper describes the enhanced separation of lomefloxacin, sparfloxacin, fleroxacin, norfloxacin, ofloxacin, gatifloxacin and pazufloxacin by capillary zone electrophoresis (CZE) using silica nanoparticles (SiNPs) as running buffer additive. The impact of SiNPs concentration on the resolution and selectivity of separation
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.